Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients

Launched by THE GENERAL HOSPITAL OF WESTERN THEATER COMMAND · Sep 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether a substance called mesenchymal stem cell (MSC) culture supernatant can help prevent and treat injuries to the mucous membranes in patients who have undergone hematopoietic stem cell transplantation (HSCT). HSCT is a treatment often used for blood cancers, but it can lead to painful injuries in the mouth, skin, and bladder due to chemotherapy and radiation. The aim of the study is to see if MSC culture supernatant can promote healing and reduce inflammation, potentially improving patients' recovery and quality of life without the risks associated with using live stem cells.

To be eligible for this trial, participants need to be 18 years or older, have had HSCT, and developed mucosal injuries as a result of their treatment. Those who join will be randomly placed into one of two groups: one will receive standard care, while the other will get MSC culture supernatant. The study, which will involve 120 patients and last about five years, will monitor participants for any side effects and how well the treatment works. This research could lead to better ways to manage the painful side effects of cancer treatments, ultimately helping patients feel better during their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants aged 18 years or older.
• • Patients who have undergone hematopoietic stem cell transplantation (HSCT).
• • Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.
• • Patients who are willing to provide informed consent and comply with the study procedures.
• Exclusion Criteria:
• • Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.
• • Patients with uncontrolled active infections.
• • Known allergies or hypersensitivity to MSC supernatant.
• • Pregnant or breastfeeding women.
• • Patients with HIV or active hepatitis B or C infections.
• • Patients who have participated in another clinical trial within the last 4 weeks.